Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease

Richard K Burt*, Malcolm Brenner, William Burns, Eva Courier, Gary Firestein, Bevra Hahn, Helen Heslop, Charles Link, Henry McFarland, Martin Roland, Mary Territo, George Tsokos, Ann Traynor

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

12 Scopus citations

Abstract

In phase I (safety) trials, we have demonstrated the feasibility of autologous hematopoietic stem cell transplantation (HSCT) for patients with autoimmune diseases. Although this review comments on results of our phase I trials, the focus is on phase II (efficacy) trials using gene-marked autologous stem cells.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Clinical Immunology
Volume20
Issue number1
DOIs
StatePublished - Apr 28 2000

Keywords

  • Autoimmune disease
  • Gene-marked autologous stem cells
  • Hematopoietic stem cell transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease'. Together they form a unique fingerprint.

Cite this